Document Detail


A phase I trial of CPT-11 and S-1 combination chemotherapy in patients with metastatic colorectal cancer.
MedLine Citation:
PMID:  18613376     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND/AIMS: To establish a safe and practical chemotherapeutic regimen using CPT-11 in combination with an oral 5FU derivative S-1 for patients with metastatic colorectal cancer, a phase I clinical trial was conducted in an outpatient setting. METHODOLOGY: Nine patients with metastatic colorectal cancer were enrolled. S-1 was administered at approved doses of 80 mg/body/day to eligible patients with a body surface area (BSA) of less than 1.25m2, 100 mg/body/day to those with a BSA of 1.25-1.5m2, and 120 mg/body/day to those with a BSA of more than 1.5m2, for 2 weeks followed by 1 week rest, comprising one treatment cycle of 3 weeks. CPT-11 was administered on day 8 of the S-1 cycle. The dose of CPT-11 was escalated from 60-120 mg/m2 by every 20 mg/m2 for every cohort consisting of at least 3 patients in order to define dose-limiting toxicity (DLT), maximal tolerated dose (MTD), and recommended dose (RD) in preparation for a phase II trial. RESULTS: In regard to the hematologic toxicity, a decrease of WBC to less than grade 2 was observed in 2 patients until the dose was escalated to 100 mg/m2 of CPT-11, which delayed the treatment for 1 week in 1 patient. Regarding non-hematologic toxicity, fatigue and gastrointestinal toxicity, including anorexia and nausea/vomiting, at grades 1 and 2 were commonly observed throughout the dose levels. Diarrhea at grade 3 was observed at the 4th cycle of 100 mg/m2 CPT-11 in 2 of 3 patients, both of whom required hospitalization. All patients were able to complete more than 3 treatment cycles, and 1 patient at 80 mg/m2 of CPT-11 was able to receive 31 treatment cycles. Observed tumor responses included 1 partial response (PR), 2 moderate responses, 4 stable diseases, and 2 progressive diseases. Serum CEA level decreased in 7 of the 9 patients enrolled. CONCLUSIONS: These results suggest that this treatment regimen using CPT-11 in combination with oral S-1 therapy is a safe regimen in an outpatient setting and effective for patients with metastatic colorectal cancer. The DLT is diarrhea at a MTD of 100 mg/m2 of CPT-11, and 80 mg/m2 CPT-11 is recommended for the next phase II trial.
Authors:
Yoshiyuki Yamaguchi; Kazuhito Minami; Yoshiharu Kawabuchi; Akiho Ohshita; Katsuji Hironaka
Related Documents :
14569846 - Irinotecan in esophageal cancer.
3119346 - Mitomycin c is an inactive drug in the third-line treatment of hormone and chemotherapy...
19653336 - Irinotecan therapy and molecular targets in colorectal cancer: a systemic review.
17479286 - Combination therapy of s-1 and cddp for patients with colorectal cancer.
18425006 - Extent of resection and survival in glioblastoma multiforme: identification of and adju...
24262326 - Socioeconomic deprivation and survival after stroke: findings from the prospective sout...
Publication Detail:
Type:  Case Reports; Clinical Trial, Phase I; Journal Article    
Journal Detail:
Title:  Hepato-gastroenterology     Volume:  55     ISSN:  0172-6390     ISO Abbreviation:  Hepatogastroenterology     Publication Date:    2008 Mar-Apr
Date Detail:
Created Date:  2008-07-10     Completed Date:  2008-12-04     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8007849     Medline TA:  Hepatogastroenterology     Country:  Greece    
Other Details:
Languages:  eng     Pagination:  407-11     Citation Subset:  IM    
Affiliation:
Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan. shogo@hiroshima-u.ac.jp
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Antimetabolites, Antineoplastic / administration & dosage*
Camptothecin / administration & dosage,  analogs & derivatives*
Colorectal Neoplasms / drug therapy*,  pathology
Drug Combinations
Drug Therapy, Combination
Female
Humans
Male
Middle Aged
Neoplasm Metastasis
Oxonic Acid / administration & dosage*
Tegafur / administration & dosage*
Chemical
Reg. No./Substance:
0/Antimetabolites, Antineoplastic; 0/Drug Combinations; 100286-90-6/irinotecan; 150863-82-4/S 1 (combination); 17902-23-7/Tegafur; 7689-03-4/Camptothecin; 937-13-3/Oxonic Acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Importance of thymidine phosphorylase, dihydropyrimidine dehydrogenase and thymidylate synthase expr...
Next Document:  Surgical resection for colon cancer: laparoscopic assisted vs. open colectomy.